Matches in SemOpenAlex for { <https://semopenalex.org/work/W2342175054> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2342175054 endingPage "9514" @default.
- W2342175054 startingPage "9514" @default.
- W2342175054 abstract "9514 Background: Infants (<366 days) with ALL and an MLL rearrangement (MLL-R), have a dismal prognosis. Early relapse is common and event free survival (EFS) is poor. The Children's Oncology Group (COG) parallel pilot trials, 1953 and 9407, were designed to prospectively compare early HSCT to intensified chemotherapy in infants with MLL-R ALL. This is the largest prospective trial investigating the role of HSCT in such patients (pts) in first remission (CR-1). Methods: From 1997–2000, 186 pts were registered (132 MLL-R). Both trials were identical through Induction, Induction Intensification and Re-Induction (Re-I), then diverged. Pts with MLL-R ALL with matched/one antigen mismatched - related/unrelated donors were to undergo HSCT (mandated on 1953/optional on 9407) at completion of Re-I. The HSCT regimen was ara-c, cyclophosphamide, steroid and total body irradiation; graft vs. host prophylaxis was cyclosporine. Results: Compliance with protocol mandated conditioning for HSCT was poor and 28/53 HSCT pts received non-protocol preparative regimens. By life table comparisons, the 5 year HSCT EFS was 50.9% (SE=9.9%, RHR 1.13) vs. 48.7% (SE=10.1%) p=0.68 in 47 control pts (chemotherapy-treated, MLL-R), who survived 143 days (median time to HSCT = 143 days). By statistical regression analysis the RHR for HSCT was 1.454 (90% CI 0.911, 2.318), p-value = 0.19, showing a trend in favor of chemotherapy alone. Neither donor source nor preparative regimen affected HSCT outcome. Chemotherapy outcomes were similar on 1953 and 9407. Events for HSCT pts were most common in the first 6 months: 20 events (11 HSCT related deaths/9 relapses). In the control group, 7/9 events in this time period were due to relapse. Conclusion: These results show no advantage for HSCT in CR1 in infants with MLL-R ALL. These data do not support the routine use of HSCT in CR1 in MLL-R infants. No significant financial relationships to disclose." @default.
- W2342175054 created "2016-06-24" @default.
- W2342175054 creator A5008703987 @default.
- W2342175054 creator A5019914745 @default.
- W2342175054 creator A5021059238 @default.
- W2342175054 creator A5033608060 @default.
- W2342175054 creator A5035833002 @default.
- W2342175054 creator A5036295405 @default.
- W2342175054 creator A5074136109 @default.
- W2342175054 creator A5079367282 @default.
- W2342175054 creator A5080485119 @default.
- W2342175054 creator A5085010022 @default.
- W2342175054 date "2007-06-20" @default.
- W2342175054 modified "2023-09-26" @default.
- W2342175054 title "Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL)" @default.
- W2342175054 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.9514" @default.
- W2342175054 hasPublicationYear "2007" @default.
- W2342175054 type Work @default.
- W2342175054 sameAs 2342175054 @default.
- W2342175054 citedByCount "4" @default.
- W2342175054 crossrefType "journal-article" @default.
- W2342175054 hasAuthorship W2342175054A5008703987 @default.
- W2342175054 hasAuthorship W2342175054A5019914745 @default.
- W2342175054 hasAuthorship W2342175054A5021059238 @default.
- W2342175054 hasAuthorship W2342175054A5033608060 @default.
- W2342175054 hasAuthorship W2342175054A5035833002 @default.
- W2342175054 hasAuthorship W2342175054A5036295405 @default.
- W2342175054 hasAuthorship W2342175054A5074136109 @default.
- W2342175054 hasAuthorship W2342175054A5079367282 @default.
- W2342175054 hasAuthorship W2342175054A5080485119 @default.
- W2342175054 hasAuthorship W2342175054A5085010022 @default.
- W2342175054 hasConcept C126322002 @default.
- W2342175054 hasConcept C141071460 @default.
- W2342175054 hasConcept C143998085 @default.
- W2342175054 hasConcept C2776611710 @default.
- W2342175054 hasConcept C2776694085 @default.
- W2342175054 hasConcept C2776755627 @default.
- W2342175054 hasConcept C2777408962 @default.
- W2342175054 hasConcept C2781413609 @default.
- W2342175054 hasConcept C2911091166 @default.
- W2342175054 hasConcept C535046627 @default.
- W2342175054 hasConcept C71924100 @default.
- W2342175054 hasConceptScore W2342175054C126322002 @default.
- W2342175054 hasConceptScore W2342175054C141071460 @default.
- W2342175054 hasConceptScore W2342175054C143998085 @default.
- W2342175054 hasConceptScore W2342175054C2776611710 @default.
- W2342175054 hasConceptScore W2342175054C2776694085 @default.
- W2342175054 hasConceptScore W2342175054C2776755627 @default.
- W2342175054 hasConceptScore W2342175054C2777408962 @default.
- W2342175054 hasConceptScore W2342175054C2781413609 @default.
- W2342175054 hasConceptScore W2342175054C2911091166 @default.
- W2342175054 hasConceptScore W2342175054C535046627 @default.
- W2342175054 hasConceptScore W2342175054C71924100 @default.
- W2342175054 hasIssue "18_suppl" @default.
- W2342175054 hasLocation W23421750541 @default.
- W2342175054 hasOpenAccess W2342175054 @default.
- W2342175054 hasPrimaryLocation W23421750541 @default.
- W2342175054 hasRelatedWork W1989798994 @default.
- W2342175054 hasRelatedWork W2010029499 @default.
- W2342175054 hasRelatedWork W2024219304 @default.
- W2342175054 hasRelatedWork W2077242620 @default.
- W2342175054 hasRelatedWork W2121694206 @default.
- W2342175054 hasRelatedWork W2169999184 @default.
- W2342175054 hasRelatedWork W2403510525 @default.
- W2342175054 hasRelatedWork W2712922270 @default.
- W2342175054 hasRelatedWork W2893092605 @default.
- W2342175054 hasRelatedWork W64123703 @default.
- W2342175054 hasVolume "25" @default.
- W2342175054 isParatext "false" @default.
- W2342175054 isRetracted "false" @default.
- W2342175054 magId "2342175054" @default.
- W2342175054 workType "article" @default.